Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus paclitaxel/carboplatin for platinum-sensitive recurrent ovarian cancer
ChiCTR1800015494Phase 4Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Apr 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib in ovarian cancer (2 arms), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoints: Disease control rate and Objective response rate. Started Apr 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR1800015494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015494.